This document provides a short summary of this study for a general audience. You can
find more information in the scientific summary of the study. A link to this summary is
provided at the end of this document.
Study names
Short Title: A study to assess how well GSK1358820 works and how safe it is in patients
with overactive bladder.
Full Scientific Title: A phase III study to evaluate the efficacy and safety of GSK1358820
(botulinum toxin type A) in patients with overactive bladder.
Study Number: 204947
Who sponsored this study?
GlaxoSmithKline (GSK)
GSK Clinical Support Help Desk
Website: clinicalsupporthd.gsk.com/contact.html
Email: GSKClinicalSupportHD@gsk.com
General information about the clinical study
When and where was this study done?
The study started in August 2016 and ended in November 2018. All study sites were in
Japan.
What was the main reason for this study?
Patients with overactive bladder (OAB) may have the following symptoms related to
the bladder’s abnormal storage of urine:
• Sudden urge to urinate (urinary urgency).
• Urinate more often than normal - usually more than eight times a day (urinary
frequency).
• Waking to urinate more than once at night (nocturia).
• Uncontrolled leaking of urine (urinary incontinence).
Use of the data and information contained in this Document is unrestricted, provided that it may not
be used in applications by others for regulatory approval of a product. While not required, when using
these data, we ask that proper credit or attribution of GSK as the source of the data be given. GSK
disclaims liability for all uses of the data by users of this Document, to the fullest extent permitted by
applicable law. No trademark, patent, or regulatory/data exclusivity rights held by GSK are waived,
licensed or otherwise affected.